/PRNewswire/ DelveInsight s Influenza Pipeline Insight 2022 report provides comprehensive global coverage of available, marketed, and pipeline influenza.
Sanofi continues to deliver strong business EPS(1) growth driven by higher sales and improved margins in Q1 Paris, April 28, 2022 Q1 2022 sales growth of 8.6% at CER driven by Dupixent and CHC